 [1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or decrease the risk of [0m
[34mangioedema?[0m
 [1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes METOPROLOL TARTRATE increase the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"METOPROLOL TARTRATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m4[0m[31m%  [0m[1;31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m23.2[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31mBradycardia [0m[1;31m([0m[31mheart rate &lt;[0m[1;31m40[0m[31m beats/min[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m15.9[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m6.7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m
[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> Second- or third-degree heart block  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m4.7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m4[0m[31m. METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> First-degree heart block [0m[1;31m([0m[31mP-R [0m
[31m&#x2265;[0m[1;31m0.26[0m[31m sec[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m5.3[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m1.9[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31mHeart failure  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m27.5[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m29[0m[31m. METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m6[0m[31m%  [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: adverse_reactions: ADVERSE REACTIONS Hypertension and Angina Most adverse effects have been mild and transient. Central Nervous System: Tiredness and dizziness have [0m
[31moccurred in about [0m[1;31m10[0m[31m of [0m[1;31m100[0m[31m patients. Depression has been reported in about [0m[1;31m5[0m[31m of [0m[1;31m100[0m[31m patients. Mental confusion and short-term memory loss have been reported. Headache, nightmares, and insomnia have [0m
[31malso been reported. Cardiovascular: Shortness of breath and bradycardia have occurred in approximately [0m[1;31m3[0m[31m of [0m[1;31m100[0m[31m patients. Cold extremities; arterial insufficiency, usually of the Raynaud type; [0m
[31mpalpitations; congestive heart failure; peripheral edema; and hypotension have been reported in about [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. Gangrene in patients with pre-existing severe peripheral circulatory disorders [0m
[31mhas also been reported very rarely. [0m[1;31m([0m[31mSee CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS . METOPROLOL TARTRATE: adverse_reactions: [0m[1;31m)[0m[31m Respiratory: Wheezing [0m[1;31m([0m[31mbronchospasm[0m[1;31m)[0m[31m and dyspnea have been reported [0m
[31min about [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Rhinitis has also been reported. Gastrointestinal: Diarrhea has occurred in about [0m[1;31m5[0m[31m of [0m[1;31m100[0m[31m patients. Nausea, dry mouth, gastric pain, constipation, [0m
[31mflatulence, and heartburn have been reported in about [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. Vomiting was a common occurrence. Postmarketing experience reveals very rare reports of hepatitis, jaundice and non-specific [0m
[31mhepatic dysfunction. Isolated cases of transaminase, alkaline phosphatase, and lactic dehydrogenase elevations have also been reported. Hypersensitive Reactions: Pruritus or rash have occurred in [0m
[31mabout [0m[1;31m5[0m[31m of [0m[1;31m100[0m[31m patients. Very rarely, photosensitivity and worsening of psoriasis has been reported. METOPROLOL TARTRATE: adverse_reactions: Miscellaneous: Peyronie’s disease has been reported in [0m
[31mfewer than [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m,[0m[1;31m000[0m[31m patients. Musculoskeletal pain, blurred vision, and tinnitus have also been reported. There have been rare reports of reversible alopecia, agranulocytosis, and dry eyes. [0m
[31mDiscontinuation of the drug should be considered if any such reaction is not otherwise explicable. There have been very rare reports of weight gain, arthritis, and retroperitoneal fibrosis [0m
[1;31m([0m[31mrelationship to metoprolol has not been definitely established[0m[1;31m)[0m[31m. The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with metoprolol. Myocardial [0m
[31mInfarction Central Nervous System: Tiredness has been reported in about [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. Vertigo, sleep disturbances, hallucinations, headache, dizziness, visual disturbances, confusion, and reduced[0m
[31mlibido have also been reported, but a drug relationship is not clear.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: drug_interactions: Alpha-adrenergic Agents: Antihypertensive effect of alpha-adrenergic blockers such as guanethidine, betanidine, reserpine, alpha-methyldopa or [0m
[31mclonidine may be potentiated by beta-blockers including metoprolol. Beta-adrenergic blockers may also potentiate the postural hypotensive effect of the first dose of prazosin, probably by preventing [0m
[31mreflex tachycardia. On the contrary, beta adrenergic blockers may also potentiate the hypertensive response to withdrawal of clonidine in patients receiving concomitant clonidine and beta-adrenergic [0m
[31mblocker. If a patient is treated with clonidine and metoprolol concurrently, and clonidine treatment is to be discontinued, stop metoprolol several days before clonidine is withdrawn. Rebound [0m
[31mhypertension that can follow withdrawal of clonidine may be increased in patients receiving concurrent beta-blocker treatment. METOPROLOL TARTRATE: precautions: Ergot Alkaloid: Concomitant [0m
[31madministration with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids. Dipyridamole: In general, administration of a beta-blocker should be withheld before dipyridamole testing,[0m
[31mwith careful monitoring of heart rate following the dipyridamole injection. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have been conducted to evaluate [0m
[31mcarcinogenic potential. In a [0m[1;31m2[0m[31m-year study in rats at three oral dosage levels of up to [0m[1;31m800[0m[31m mg/kg per day, there was no increase in the development of spontaneously occurring benign or malignant [0m
[31mneoplasms of any type. The only histologic changes that appeared to be drug related were an increased incidence of generally mild focal accumulation of foamy macrophages in pulmonary alveoli and a [0m
[31mslight increase in biliary hyperplasia. METOPROLOL TARTRATE: precautions: In a [0m[1;31m21[0m[31m-month study in Swiss albino mice at three oral dosage levels of up to [0m[1;31m750[0m[31m mg/kg per day, benign lung tumors [0m[1;31m([0m[31msmall [0m
[31madenomas[0m[1;31m)[0m[31m occurred more frequently in female mice receiving the highest dose than in untreated control animals. There was no increase in malignant or total [0m[1;31m([0m[31mbenign plus malignant[0m[1;31m)[0m[31m lung tumors, or in [0m
[31mthe overall incidence of tumors or malignant tumors. This [0m[1;31m21[0m[31m-month study was repeated in CD-[0m[1;31m1[0m[31m mice, and no statistically or biologically significant differences were observed between treated and [0m
[31mcontrol mice of either sex for any type of tumor. All mutagenicity tests performed [0m[1;31m([0m[31ma dominant lethal study in mice, chromosome studies in somatic cells, a Salmonella/mammalian-microsome mutagenicity [0m
[31mtest, and a nucleus anomaly test in somatic interphase nuclei[0m[1;31m)[0m[31m were negative. Reproduction toxicity studies in mice, rats and rabbits did not indicate teratogenic potential for metoprolol tartrate. [0m
[31mMETOPROLOL TARTRATE: precautions: Embryotoxicity and/or fetotoxicity in rats and rabbits were noted starting at doses of [0m[1;31m50[0m[31m mg/kg in rats and [0m[1;31m25[0m[31m mg/kg in rabbits, as demonstrated by increases in [0m
[31mpreimplantation loss, decreases in the number of viable fetuses per dose, and/or decreases in neonatal survival. High doses were associated with some maternal toxicity, and growth delay of the [0m
[31moffspring in utero , which was reflected in minimally lower weights at birth. The oral NOAELs for embryo-fetal development in mice, rats, and rabbits were considered to be [0m[1;31m25[0m[31m, [0m[1;31m200[0m[31m, and [0m[1;31m12.5[0m[31m mg/kg. [0m
[31mThis corresponds to dose levels that are approximately [0m[1;31m0.3[0m[31m, [0m[1;31m4[0m[31m, and [0m[1;31m0.5[0m[31m times, respectively, when based on surface area, the maximum human oral dose [0m[1;31m([0m[1;31m8[0m[31m mg/kg/day[0m[1;31m)[0m[31m of metoprolol tartrate. METOPROLOL [0m
[31mTARTRATE: precautions: Metoprolol tartrate has been associated with reversible adverse effects on spermatogenesis starting at oral dose levels of [0m[1;31m3.5[0m[31m mg/kg in rats [0m[1;31m([0m[31ma dose that is only [0m[1;31m0.1[0m[31m-times the [0m
[31mhuman dose, when based on surface area[0m[1;31m)[0m[31m, although other studies have shown no effect of metoprolol tartrate on reproductive performance in male rats. Pregnancy Category C Upon confirming the diagnosis[0m
[31mof pregnancy, women should immediately inform the doctor. Metoprolol has been shown to increase postimplantation loss and decrease neonatal survival in rats at doses up to [0m[1;31m11[0m[31m times the maximum daily [0m
[31mhuman dose of [0m[1;31m450[0m[31m mg, when based on surface area. Distribution studies in mice confirm exposure of the fetus when metoprolol is administered to the pregnant animal. These limited animal studies do not[0m
[31mindicate direct or indirect harmful effects with respect to teratogenicity [0m[1;31m([0m[31msee Carcinogenesis, Mutagenesis, Impairment of Fertility [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: spl_product_data_elements: Metoprolol Tartrate Metoprolol Tartrate MICROCRYSTALLINE CELLULOSE STARCH, CORN SODIUM STARCH GLYCOLATE TYPE A POTATO SILICON DIOXIDE SODIUM [0m
[31mLAURYL SULFATE TALC MAGNESIUM STEARATE HYPROMELLOSE [0m[1;31m2910[0m[31m [0m[1;31m([0m[1;31m6[0m[31m MPA. METOPROLOL TARTRATE: spl_product_data_elements: [0m[1;31m)[0m[31m TITANIUM DIOXIDE POLYETHYLENE GLYCOL [0m[1;31m400[0m[31m POLYSORBATE [0m[1;31m80[0m[31m METOPROLOL TARTRATE [0m
[31mMETOPROLOL C;[0m[1;31m73[0m[31m         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: indications_and_usage: INDICATIONS AND USAGE Hypertension Metoprolol tartrate tablets, USP are indicated for the treatment of hypertension. They may be used alone or in [0m
[31mcombination with other antihypertensive agents. Angina Pectoris Metoprolol tartrate tablets, USP are indicated in the long-term treatment of angina pectoris. Myocardial Infarction Metoprolol tartrate [0m
[31mtablets, USP are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in [0m
[31mconjunction with intravenous metoprolol. Oral metoprolol tartrate tablets, USP therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within [0m[1;31m3[0m[31m to [0m[1;31m10[0m[31m [0m
[31mdays of the acute event [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: brand_name         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: package_ndc         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_set_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: dosage_and_administration: DOSAGE AND ADMINISTRATION Hypertension Individualized the dosage of metoprolol tartrate tablets. Metoprolol tartrate tablets should be taken [0m
[31mwith or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily in single or divided doses, whether used alone or added to a diuretic. Increase the dosage [0m
[31mat weekly [0m[1;31m([0m[31mor longer[0m[1;31m)[0m[31m intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after [0m[1;31m1[0m[31m week of therapy. The effective [0m
[31mdosage range of metoprolol tartrate tablets is [0m[1;31m100[0m[31m to [0m[1;31m450[0m[31m mg per day. Dosages above [0m[1;31m450[0m[31m mg per day have not been studied. METOPROLOL TARTRATE: dosage_and_administration: While once-daily dosing is [0m
[31meffective and can maintain a reduction in blood pressure throughout the day, lower doses [0m[1;31m([0m[31mespecially [0m[1;31m100[0m[31m mg[0m[1;31m)[0m[31m may not maintain a full effect at the end of the [0m[1;31m24[0m[31m-hour period, and larger or more [0m
[31mfrequent daily doses may be required. This can be evaluated by measuring blood pressure near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the[0m
[31mday. Beta [0m[1;31m1[0m[31m selectivity diminishes as the dose of metoprolol is increased. Angina Pectoris The dosage of metoprolol tartrate tablets should be individualized. Metoprolol tartrate tablets should be [0m
[31mtaken with or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily, given in two divided doses. Gradually increase the dosage at weekly intervals until [0m
[31moptimum clinical response has been obtained or there is pronounced slowing of the heart rate. METOPROLOL TARTRATE: dosage_and_administration: The effective dosage range of metoprolol tartrate tablets [0m
[31mis [0m[1;31m100[0m[31m to [0m[1;31m400[0m[31m mg per day. Dosages above [0m[1;31m400[0m[31m mg per day have not been studied. If treatment is to be discontinued, gradually decrease the dosage over a period of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m weeks [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. [0m
[31mMyocardial Infarction Early Treatment During the early phase of definite or suspected acute myocardial infarction, initiate treatment with metoprolol tartrate tablets as soon as possible after the [0m
[31mpatient's arrival in the hospital. Such treatment should be initiated in a coronary care or similar unit immediately after the patient’s hemodynamic condition has stabilized. Begin treatment in this [0m
[31mearly phase with the intravenous administration of three bolus injections of [0m[1;31m5[0m[31m mg of metoprolol tartrate each; give the injections at approximately [0m[1;31m2[0m[31m-minute intervals. During the intravenous [0m
[31madministration of metoprolol, monitor blood pressure, heart rate, and electrocardiogram. METOPROLOL TARTRATE: dosage_and_administration: In patients who tolerate the full intravenous dose [0m[1;31m([0m[1;31m15[0m[31m mg[0m[1;31m)[0m[31m, [0m
[31minitiate metoprolol tartrate tablets, [0m[1;31m50[0m[31m mg every [0m[1;31m6[0m[31m hours, [0m[1;31m15[0m[31m minutes after the last intravenous dose and continue for [0m[1;31m48[0m[31m hours. Thereafter, the maintenance dosage is [0m[1;31m100[0m[31m mg twice daily [0m[1;31m([0m[31msee Late [0m
[31mTreatment below[0m[1;31m)[0m[31m. Start patients who appear not to tolerate the full intravenous dose on metoprolol tartrate tablets either [0m[1;31m25[0m[31m mg or [0m[1;31m50[0m[31m mg every [0m[1;31m6[0m[31m hours [0m[1;31m([0m[31mdepending on the degree of intolerance[0m[1;31m)[0m[31m [0m[1;31m15[0m[31m [0m
[31mminutes after the last intravenous dose or as soon as their clinical condition allows. In patients with severe intolerance, discontinue metoprolol tartrate tablets [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. METOPROLOL [0m
[31mTARTRATE: dosage_and_administration: Late Treatment Start patients with contraindications to treatment during the early phase of suspected or definite myocardial infarction, patients who appear not to[0m
[31mtolerate the full early treatment, and patients in whom the physician wishes to delay therapy for any other reason on metoprolol tartrate tablets, [0m[1;31m100[0m[31m mg twice daily, as soon as their clinical [0m
[31mcondition allows. Continue therapy for at least [0m[1;31m3[0m[31m months. Although the efficacy of metoprolol beyond [0m[1;31m3[0m[31m months has not been conclusively established, data from studies with other beta-blockers suggest [0m
[31mthat treatment should be continued for [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m years. Special Populations Pediatric Patients : No pediatric studies have been performed. The safety and efficacy of metoprolol tartrate tablets in [0m
[31mpediatric patients have not been established. Renal Impairment : No dose adjustment of metoprolol tartrate tablets is required in patients with renal impairment. METOPROLOL TARTRATE: [0m
[31mdosage_and_administration: Hepatic Impairment : Metoprolol blood levels are likely to increase substantially in patients with hepatic impairment. Therefore, metoprolol tartrate tablets should be [0m
[31minitiated at low doses with cautious gradual dose titration according to clinical response. Geriatric Patients [0m[1;31m([0m[1;31m>[0m[1;31m65[0m[31m years[0m[1;31m)[0m[31m : In general, use a low initial starting dose in elderly patients given their[0m
[31mgreater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Method of Administration For oral treatment, the tablets should be swallowed [0m
[31mun-chewed with a glass of water. Metoprolol tartrate tablets should always be taken in standardized relation with meals. If the physician asks the patient to take metoprolol tartrate tablets either [0m
[31mbefore breakfast or with breakfast, then the patient should continue taking metoprolol with the same schedule during the course of therapy.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: adverse_reactions: Cardiovascular: In the randomized comparison of metoprolol and placebo described in the CLINICAL PHARMACOLOGY section, the following adverse reactions [0m
[31mwere reported: Metoprolol Placebo Hypotension [0m[1;31m([0m[31msystolic BP < [0m[1;31m90[0m[31m mmHg[0m[1;31m)[0m[31m [0m[1;31m27.4[0m[31m% [0m[1;31m23.2[0m[31m% Bradycardia [0m[1;31m([0m[31mheart rate <[0m[1;31m40[0m[31m beats/min[0m[1;31m)[0m[31m [0m[1;31m15.9[0m[31m% [0m[1;31m6.7[0m[31m% Second- or third-degree heart block [0m[1;31m4.7[0m[31m% [0m[1;31m4.7[0m[31m% First-degree heart [0m
[31mblock [0m[1;31m([0m[31mP-R ≥[0m[1;31m0.26[0m[31m sec[0m[1;31m)[0m[31m [0m[1;31m5.3[0m[31m% [0m[1;31m1.9[0m[31m% Heart failure [0m[1;31m27.5[0m[31m% [0m[1;31m29.6[0m[31m% Respiratory: Dyspnea of pulmonary origin has been reported in fewer than [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. Gastrointestinal: Nausea and abdominal pain have [0m
[31mbeen reported in fewer than [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. METOPROLOL TARTRATE: adverse_reactions: Dermatologic: Rash and worsened psoriasis have been reported, but a drug relationship is not clear. [0m
[31mMiscellaneous: Unstable diabetes and claudication have been reported, but a drug relationship is not clear. Potential Adverse Reactions A variety of adverse reactions not listed above have been [0m
[31mreported with other beta-adrenergic blocking agents and should be considered potential adverse reactions to metoprolol. Central Nervous System: Reversible mental depression progressing to catatonia; [0m
[31man acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on [0m
[31mneuropsychometrics. Cardiovascular: Intensification of AV block [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. Hematologic: Agranulocytosis, nonthrombocytopenic purpura and thrombocytopenic purpura. METOPROLOL TARTRATE: [0m
[31madverse_reactions: Hypersensitive Reactions: Fever combined with aching and sore throat, laryngospasm and respiratory distress. Postmarketing Experience The following adverse reactions have been [0m
[31mreported during postapproval use of metoprolol: confusional state, an increase in blood triglycerides and a decrease in High Density Lipoprotein [0m[1;31m([0m[31mHDL[0m[1;31m)[0m[31m. Because these reports are from a population of [0m
[31muncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: precautions: PRECAUTIONS Risk of Anaphylactic Reactions While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may [0m
[31mbe more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. Information [0m
[31mfor Patients Advise patients to take metoprolol regularly and continuously, as directed, with or immediately following meals. If a dose should be missed, the patient should take only the next [0m
[31mscheduled dose [0m[1;31m([0m[31mwithout doubling it[0m[1;31m)[0m[31m. Patients should not discontinue metoprolol without consulting the physician. METOPROLOL TARTRATE: precautions: Advise patients [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m to avoid operating automobiles [0m
[31mand machinery or engaging in other tasks requiring alertness until the patient’s response to therapy with metoprolol has been determined; [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m to contact the physician if any difficulty in breathing [0m
[31moccurs; [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m to inform the physician or dentist before any type of surgery that he or she is taking metoprolol. Drug Interactions Catecholamine-depleting Drugs: Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., [0m
[31mreserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents or monoamine oxidase [0m[1;31m([0m[31mMAO[0m[1;31m)[0m[31m inhibitors. Observe patients treated with metoprolol plus a catecholamine depletor for evidence [0m
[31mof hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. METOPROLOL TARTRATE: precautions: In addition, possibly significant hypertension may theoretically [0m
[31moccur up to [0m[1;31m14[0m[31m days following discontinuation of the concomitant administration with an irreversible MAO inhibitor. Digitalis Glycosides and Beta-blockers: Both digitalis glycosides and beta-blockers [0m
[31mslow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Monitor heart rate and PR interval. Calcium Channel Blockers: Concomitant administration[0m
[31mof a beta-adrenergic antagonist with a calcium channel blocker may produce an additive reduction in myocardial contractility because of negative chronotropic and inotropic effects. CYP2D6 Inhibitors: [0m
[31mPotent inhibitors of the CYP2D6 enzyme may increase the plasma concentration of metoprolol which would mimic the pharmacokinetics of CYP2D6 poor metabolizer [0m[1;31m([0m[31msee Pharmacokinetics section[0m[1;31m)[0m[31m. Increase in[0m
[31mplasma concentrations of metoprolol would decrease the cardioselectivity of metoprolol.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the METOPROLOL TARTRATE label does not indicate that METOPROLOL TARTRATE increases the risk of angioedema. The adverse reactions section lists various side [0m
[32meffects, but angioedema is not mentioned as a common or rare adverse effect.[0m

[32mSOURCE: METOPROLOL TARTRATE label[0m
[32mEXTRACT_START_END: METOPROLOL TARTRATE: adverse_reactions: [0m[32m...[0m[32m and worsening of psoriasis has been reported.[0m
*[1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the METOPROLOL TARTRATE [0m
[34mlabel does not indicate that METOPROLOL TARTRATE increases the risk of angioedema. The adverse reactions section lists various side effects, but angioedema is not mentioned as a common or rare adverse[0m
[34meffect.[0m

[34mSOURCE: METOPROLOL TARTRATE label[0m
[34mEXTRACT_START_END: METOPROLOL TARTRATE: adverse_reactions: [0m[34m...[0m[34m and worsening of psoriasis has been reported.[0m
 [1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether METOPROLOL TARTRATE increases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the METOPROLOL TARTRATE label does not indicate that METOPROLOL TARTRATE increases the risk of angioedema and that angioedema is not mentioned as a common or rare [0m
[32madverse effect in the adverse reactions section."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The risk of angioedema is not mentioned in the METOPROLOL TARTRATE label, indicating that there is no known increase or decrease in risk associated with METOPROLOL TARTRATE according to[0m
[32mthe FDA label information."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does METOPROLOL TARTRATE increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether METOPROLOL TARTRATE increases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the METOPROLOL TARTRATE label does not indicate that METOPROLOL TARTRATE increases the risk of angioedema and that angioedema is not mentioned as a common or rare [0m
[34madverse effect in the adverse reactions section."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The risk of angioedema is not mentioned in the METOPROLOL TARTRATE label, indicating that there is no known increase or decrease in risk associated with METOPROLOL TARTRATE according to[0m
[34mthe FDA label information."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does METOPROLOL TARTRATE increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether METOPROLOL TARTRATE increases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler responded that the METOPROLOL TARTRATE label does not indicate that METOPROLOL TARTRATE increases the risk of angioedema and that angioedema is not mentioned as a common or rare adverse [0m
[31meffect in the adverse reactions section.[0m
[31m        -----[0m
[31m        Final answer: The risk of angioedema is not mentioned in the METOPROLOL TARTRATE label, indicating that there is no known increase or decrease in risk associated with METOPROLOL TARTRATE [0m
[31maccording to the FDA label information.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe risk of angioedema is not mentioned in the METOPROLOL TARTRATE label, indicating that there is no known increase or decrease in risk associated with METOPROLOL TARTRATE according to the FDA label [0m
[32minformation.[0m
